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Summary
Recent papers have attributed arrhythmic substrate in murine RyR2-P2328S hearts to 
reduced action potential (AP) conduction velocities (CV), reflecting acute functional 
inhibition and/or reduced expression of sodium channels. We explored for acute 
 effects of direct exchange protein directly activated by cAMP (Epac)- mediated ryano-
dine receptor- 2 (RyR2) activation on arrhythmic substrate and CV. Monophasic action 
potential (MAP) recordings demonstrated that initial steady (8 Hz) extrinsic pacing elic-
ited ventricular tachycardia (VT) in 0 of 18 Langendorff- perfused wild- type mouse ven-
tricles before pharmacological intervention. The Epac activator 8- CPT (8- (4- chlorophe
nylthio)- 2′- O- methyladenosine- 3′,5′- cyclic monophosphate) (VT in 1 of 7 hearts), and 
the RyR2 blocker dantrolene, either alone (0 of 11) or with 8- CPT (0 of 9) did not then 
increase VT incidence (P>.05). Both progressively increased pacing rates and pro-
grammed extrasystolic (S2) stimuli similarly produced no VT in untreated hearts (n=20 
and n=9 respectively). 8- CPT challenge then increased VT incidences (5 of 7 and 4 of 8 
hearts respectively; P<.05). However, dantrolene, whether alone (0 of 10 and 1 of 13) 
or combined with 8- CPT (0 of 10 and 0 of 13) did not increase VT incidence relative to 
those observed in untreated hearts (P>.05). 8- CPT but not dantrolene, whether alone 
or combined with 8- CPT, correspondingly increased AP latencies (1.14±0.04 (n=7), 
1.04±0.03 (n=10), 1.09±0.05 (n=8) relative to respective control values). In contrast, 
AP durations, conditions for 2:1 conduction block and ventricular effective refractory 
periods remained unchanged throughout. We thus demonstrate for the first time that 
acute RyR2 activation reversibly induces VT in specific association with reduced CV.
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1  | INTRODUCTION
Abnormal Ca2+ homeostasis increases risks of cardiac arrhythmia.1,2 For 
example, increases in cardiomyocyte intracellular [Ca2+] arising from 
increased ryanodine receptor- 2 (RyR2)- mediated sarcoplasmic retic-
ular Ca2+ release activity2 could increase sodium–calcium exchanger 
activity, thereby producing delayed afterdepolarizations and prema-
ture ventricular beats.3-5 When superimposed upon an  arrhythmic 
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substrate, typically resulting from altered action potential (AP) con-
duction or recovery properties, this could trigger cardiac  arrhythmias.6 
Recent studies have reported reduced atrial7 and ventricular conduc-
tion velocities (CV)8,9 that could potentially cause  re- entrant arrhyth-
mic substrate in murine models of catecholaminergic polymorphic 
ventricular tachycardia (CPVT) carrying the RyR2-P2328S mutation. 
This was attributed to acute effects of altered intracellular Ca2+ on 
Na+ channel (Nav1.5) function
7-9 and/or sustained downregulation of 
Nav1.5 membrane expression.
9-18
The present experiments assessed whether acute manipulations 
of Ca2+ homeostasis could influence CV and introduce arrhythmic 
substrate in wild- type hearts expressing normal RyR2, as opposed to 
RyR2-P2328S hearts. They complement recent studies that had mod-
ified Ca2+ homeostasis through exchange protein directly activated 
by cAMP (Epac) activation of RyR2- Ca2+ release channels19 through a 
phosphokinase A (PKA)- independent pathway.20,21 These studies had 
demonstrated that Epac activation increased Ca2+ spark frequencies 
in adult rat cardiac  myocytes,22 amplitudes of Ca2+- dependent Ca2+ 
 release after isoproterenol treatment,23 and amplitudes and frequen-
cies of spontaneous Ca2+  release in mouse ventricular cardiomyo-
cytes.24 They also confirmed that Epac activation acutely increased 
the incidence of both VT and triggered activity,24 in an absence of ar-
rhythmic substrate attributable to altered AP recovery properties. AP 
durations (APD) and ventricular effective refractory periods (VERPs) 
thus remained unchanged. However, these experiments had not inves-
tigated for changes in CV.
The present experiments therefore explored for arrhythmic suscep-
tibility in relationship to alterations in conduction latency as a measure 
of CV, and to VERP and APD. It did so under conditions both of Epac 
activation by 8- CPT (8- pCPT- 2′- O- Me- cAMP: 8- (4- chlorophenylthio)
- 2′- O- methyladenosine- 3′,5′- cyclic monophosphate),19 and of RyR2- 
antagonism by dantrolene.25 The latter was both applied alone, and in 
combination with Epac activation by 8- CPT. Dantrolene is known to 
inhibit diastolic Ca2+ release, decrease the frequency and duration of 
aberrant Ca2+ sparks in cultures of myocytes modelling CPVT,26 and 
heart failure.27,28 It also increases the threshold for Ca2+- induced- Ca2+- 
release from the sarcoplasmic reticulum in myocytes from failing but 
not control rabbit hearts.28 The present study thus additionally throws 
light on the use of dantrolene in a potential therapeutic approach for 
the management of Ca2+- mediated ventricular arrhythmias.
2  | RESULTS
Figures 1-3 illustrate results from Langendorff- perfused hearts sub-
jected to up to three separate pacing protocols simulating different 
in vivo patterns of electrical activity in the heart. Recordings during 
the initial regular 8 Hz pacing stimuli, simulating in vivo steady state 
resting heart rates, corresponding to a basic cycle length (BCL) of 
125 ms (Figure 1A), yielded left ventricular monophasic action po-
tential (MAP) waveforms. Quantifications were performed only on 
MAP traces that fulfilled three criteria: (i) a clear established baseline 
preceding the MAPs; (ii) any stimulus artifact that was present being 
transient, with a rapid upstroke and falling phase; and (iii) repolariza-
tion from the peak of the MAP back to the baseline being monophasic. 
The vertical markers below each MAP trace (Figure 1B) indicate tim-
ings of successive pacing stimuli.
Results were first compared between hearts studied under control 
conditions (Figure 1B(i)), and following exposure to Epac activation 
by 8- CPT (8- pCPT- 2′- O- Me- cAMP: 8- (4- chlorophenylthio)- 2′- O- met
hyladenosine- 3′,5′- cyclic monophosphate); Figure 1B(ii)). The exper-
iments then assessed the actions of the ryanodine receptor- 2 (RyR2) 
inhibitor dantrolene (Figure 1B(iii)) and a combination of 8- CPT and 
dantrolene (Figure 1B(iv)), as detailed in the Methods. MAP recordings 
were used to obtain latencies, a surrogate measure for conduction ve-
locity (CV), action potential durations at 90% recovery (APD90), and 
permitted quantifications of the frequency of spontaneous VT. No ar-
rhythmia was observed with this initial pacing in control experiments 
(0 of 18). Challenge by 8- CPT, dantrolene or dantrolene in combination 
with 8- CPT all did not increase the incidence of arrhythmia (VT in 1 of 
7, 0 of 11, and 0 of 9 hearts respectively; all P>.05).
Figure 2A illustrates the incremental pacing protocol that con-
sisted of multiple repeats of stimulus trains each containing 100 beats 
F IGURE  1 Steady (8 Hz) pacing simulating resting heart rate. 
(A) 8 Hz steady state protocol used to pace the heart at resting 
heart rate. Vertical markers below each monophasic action potential 
(MAP) trace marks the timing of successive pacing stimuli. (B) Typical 
MAP traces recorded from the left ventricle of wild- type (WT) mice 
hearts perfused with either (i) control solution alone, (ii) 8- CPT, (iii) 
dantrolene, or (iv) dantrolene with 8- CPT
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at a defined BCL. It began by imposing a BCL of 154 ms. BCL was 
then decreased by 5 ms for each new set of stimulus trains (Figure 2A). 
This simulated the effect of progressively increasing heart rates. The 
incremental pacing protocols culminated in either a 2:1 loss of cap-
ture (where one AP is triggered for every two consecutive stimuli: 
Figure 2B and C(i)), which provided a measure of refractory period, 
or VT (Figure 2C(ii)). In the control hearts, and hearts perfused with 
either dantrolene alone, or dantrolene with 8- CPT the incremental 
pacing protocol always culminated in a 2:1 block at high BCLs. This 
is exemplified in a trace (Figure 2B) obtained from a control heart, 
where there are exactly 0.5 times the number of recorded MAPs 
compared to the number of stimuli. In contrast, incremental pacing in 
hearts perfused with 8- CPT (Figure 2C) culminated in either 2:1 block 
(Figure 2C(i)), or in VT (Figure 2C(ii)). Waveforms of consecutive action 
potentials observed under such conditions of 2:1 block often showed 
an alternans pattern. The latter is known to presage an onset of major 
cardiac arrhythmias in both murine and human hearts.29 Figure 2C(ii) 
illustrates a genesis of VT: regular MAPs were recorded at a stimulus 
BCL of 44 ms. At the arrow, stimulus interval was reduced to 39 ms, 
and this was followed by an episode of irregular AP firing that eventu-
ally developed into VT (marked by square bracket).
Table 1 correspondingly demonstrates significant (P<.05) increases 
in the incidence of arrhythmia with challenge by 8- CPT. Although dan-
trolene administered alone had no significant impact on incidence 
of VT, when applied with 8- CPT, dantrolene reversed the arrhyth-
mic effects of 8- CPT (8- CPT vs dantrolene+8- CPT; P<.05; control vs 
dantrolene+8- CPT; P>.05) (Table 1).
Figure 3 illustrates results obtained from programmed applica-
tions of extrasystolic (S2) stimuli using the S1S2 programmed electri-
cal stimulation (S1S2 PES) protocol, simulating effects of extrasystolic 
events that might provoke arrhythmia in the presence of re- entrant 
substrate. This consisted of runs of repeated stimulus trains, each 
composed of eight stimuli paced at 8 Hz followed by an S2 stimu-
lus. The stimulus interval between the S2 and preceding S1 stimulus 
(known as the ‘S1S2 stimulus interval’) was shortened by 1 ms each 
time the stimulus train repeated, beginning at 124 ms (Figure 3A). 
With shortened S1S2 intervals, hearts perfused with control solu-
tion containing no drugs (Figure 3B(i)), dantrolene (Figure 3B(iii)), and 
dantrolene combined with 8- CPT (Figure 3B(iv)) became refractory 
to the S2 stimulation, as reflected in the absence of an MAP after 
the S2 stimulus. This S1S2 stimulus interval therefore corresponds 
to the VERP.
In contrast, with 8- CPT treatment (Figure 3B(ii)), instead of a loss of 
AP firing in response to the S2 stimulus, shortening of the S1S2 stimu-
lus interval frequently resulted in VT. During quantification of such re-
sults, the S1S2 PES protocol was always repeated at least once in the 
same heart under the same condition to confirm observations made 
during the first run of the protocol. In agreement with results from the 
incremental pacing protocol, the S1S2 PES procedure demonstrated 
that challenge by 8- CPT (P<.05) but not by dantrolene alone (P>.05) 
significantly increased arrhythmic incidence but that dantrolene re-
versed these arrhythmic effects of 8- CPT (8- CPT vs dantrolene+8- 
CPT, P<.05; control vs dantrolene+8- CPT, P>.05) (Table 1).
Determinations of control AP parameters prior to 8- CPT chal-
lenge gave control values of latency (16.81±1.20 ms, n=7), APD90 
(43.99±4.42 ms, n=5), VERPs (43.00±6.63 ms, n=7), and BCL values 
at the onset of 2:1 block during incremental pacing (41.00±4.54 ms 
(n=4)). Values of APD90 and VERPs had also been measured by the 
earlier study24 and agree with the present findings. Results from the 
subsequent experimental manouevres were accordingly normalized to 
control values.
Table 2 explores for changes in AP parameters as a result of chal-
lenge using 8- CPT, dantrolene, or dantrolene in combination with 8- 
CPT, by normalizing each test value against the corresponding control 
value in the same heart before pharmacological challenge. The result-
ing values of latency, APD90, BCL at onset of 2:1 block, and VERP were 
F IGURE  2 Hearts paced with the incremental pacing protocol 
to investigate effect of progressively increasing steady HRs. (A) 
An incremental pacing protocol was applied, with each stimulus 
train composed of 100 stimulations, starting at a basic cycle length 
(BCL) of 154 ms. The BCL was decreased by 5 ms for each new 
set of stimulus trains. Each run of the incremental pacing protocol 
consisted of multiple repeats of stimulus trains. The BCL decreased 
until it was shorter than the ventricular refractory period. This 
appeared as the point of onset of sustained 2:1 block (1 AP fired for 
every 2 stimuli), always observed in hearts perfused with control 
solution, dantrolene alone, or dantrolene with 8- CPT. (B) Example 
of 2:1 block in a control heart. (C) In contrast, protocols performed 
in hearts treated with 8- CPT may culminate in (i) 2:1 block or 
(ii) arrhythmia in the form of ventricular tachycardia (VT). The 
occurrence of each action potential is marked with an arrow below 
the stimulus time marking
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statistically assessed for significant differences. It was seen that 8- CPT 
significantly increased AP conduction latency (vs controls: P<.01; n=7). 
However, it had no effect on the AP recovery parameters of APD90, 
BCL at onset of 2:1 block, and VERP (vs control: all P>.05; n=5, n=4, 
and n=7 respectively). In contrast, dantrolene alone did not affect ei-
ther the AP activation or recovery parameters (P>.05; latency: n=10, 
APD90: n=8; BCL at onset of 2:1 block: n=5; VERP: n=7). However, 
results obtained following addition of 8- CPT combined with dantro-
lene demonstrated that dantrolene reversed the effect of 8- CPT on 
latency. It then yielded latencies indistinguishable from the control val-
ues (dantrolene+8- CPT vs control: P>.05; n=7) and preserved normal 
AP recovery parameters (dantrolene+8- CPT vs control: P>.05; n=7).
Together these findings suggest actions of Epac- mediated RyR2 
activation by 8- CPT both increases the incidence of arrhythmia fol-
lowing extrasystolic, and incremental pacing and reduces CV without 
affecting AP recovery properties. The RyR2 blocker dantrolene did not 
produce such changes. However, it reversed both the pro- arrhythmic 
actions of 8- CPT, and its actions on CV. The findings are thus consis-
tent with acute pro- arrhythmic actions of RyR2 receptor modulation 
on both CV and arrhythmia, adding to previous studies implicating 
chronic alterations in Na+ channel protein expression reported with 
genetic modifications of RyR2.
3  | DISCUSSION
This study explored the effects of acute interventions involving the 
ryanodine receptor (RyR2)- Ca2+ release channel on arrhythmogen-
esis and its relationship to alterations in AP conduction velocity 
(CV) in isolated perfused wild- type (WT) murine hearts. Previous 
studies had reported that: (i) The RyR2-P2328S modification, as-
sociated with human catecholaminergic polymorphic ventricular 
tachycardia (CPVT) resulted in increased arrhythmic tendency and 
increased RyR2- mediated Ca2+ release in murine ventricles.30 (ii) 
This was accompanied by reductions in the CVs of both ventricular7 
and atrial APs that could potentially create arrhythmic substrates.8,9 
(iii) The altered Ca2+ homeostasis also appeared to modify the Na+ 
current with consequences for CV. The latter could involve (a) a 
long term downregulation of cardiac Na+ channel (Nav1.5) expres-
sion that was observed in both atrial9 and ventricular RyR2-P228S 
myocytes.10 WT rat cardiomyoctes similarly showed increased and 
decreased surface membrane expression of functionally active 
Nav1.5, Nav1.5 mRNA and total Nav1.5 protein following challenge 
by the Ca2+ channel blocker verapamil and the Ca2+ ionophore cal-
cimycin respectively.11,12 (b) Alternatively, acute effects of altered 
intracellular Ca2+ resulting from enhanced RyR2- mediated Ca2+ 
release might modify Na+ channel function. Nav1.5 thus contains 
two potentially directly Ca2+- sensitive regions: (i) a Ca2+- binding EF- 
hand motif13 and (ii) a calmodulin- binding IQ domain in the Nav1.5 
C- terminal region.14,15 Both these sites have been suggested to 
mediate Ca2+- mediated modulation of Na+ channel function. Thus, 
acute increases and decreases in Na+ current densities followed in-
creases or decreases in intracellular [Ca2+]. This was demonstrated 
in patch- clamped cultured neonatal rat myocytes using buffering 
by BAPTA (1,2- bis(o- aminophenoxy)ethane- N,N,N′,N′- tetraacetic 
acid tetrakis- acetoxymethyl ester) and caffeine administration re-
spectively.16,17 (iii) Additionally, Ca2+ may indirectly affect Nav1.5 
through the action of calmodulin kinase II (CamKII) on multiple phos-
phorylation sites on the channel.18
The present experiments explored the effects of acute RyR2- Ca2+ 
channel activation through the phosphokinase A (PKA)- independent 
Epac20,21 in producing VT. The experiments employed 8- CPT 
((8- pCPT- 2′- O- Me- cAMP: 8- (4- chlorophenylthio)- 2′- O- methyladen
osine- 3′,5′- cyclic monophosphate) as Epac agonist. Despite being a 
cAMP (3′5- cyclic adenosine monophosphate) analogue, the 2- hydroxyl 
FIGURE 3 Hearts paced with the S1S2 programmed electrical 
stimulation (S1S2 PES) protocol to simulate the occurrence of 
extrasystolic beats within regular pacing. (A) The S1S2 PES protocol 
was composed of repeats of stimulus trains. Each stimulus is marked 
out by a vertical marker. Each train consisted of eight S1 stimuli ((A) 
narrow marker or (B) filled triangles indicating the first and last S1 
stimulus in each train; BCL=125 ms), followed by an extrasystolic (S2) 
stimulus (wide marker in (A) and open triangle in (B)). The interval 
between the S2 and the preceding S1 stimulus (S1S2 interval) was 
shortened by 1 ms with each repetition of the S1 stimulus train. 
The longest S1S2 interval was 124 ms. The S1S2 PES protocol was 
used to study the effects of progressively shortening S1S2 stimulus 
intervals on the generation of arrhythmia in hearts perfused with 
and without drugs. Typical results compared for hearts perfused with 
(i) control solution, (ii) 8- CPT, (iii) dantrolene, and (iv) with dantrolene 
combined with 8- CPT treatment, showing either extrasysolic 
action potentials (clear arrows), refractoriness, or an episode of VT. 
: S1 stimuli; : S2 stimuli; : MAP in response to S2 stimulus
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group substitution on its cAMP ribose moiety disrupts its interaction 
with PKA whilst permitting binding to Epac. This gives 8- CPT a 300- 
fold selectivity for Epac relative to PKA at the low, 1 μmol/L, concen-
trations employed here.19,31-33 Further reported actions of 8- CPT on 
phosphodiesterase isoforms required significantly higher inhibitory 
binding concentrations than those used here.34
Epac is implicated in adrenergically- mediated cardiac arrhythmo-
genesis.22 Previous studies reported that experimental Epac activation 
increased the frequencies and amplitudes of spontaneous Ca2+ re-
lease22,24 and the amplitudes of Ca2+ waves resulting from Ca2+- induced 
Ca2+ release.23 It was arrhythmogenic in Langendorff- perfused whole 
hearts,24 likely through altered Ca2+ homestasis following its interac-
tion with and opening of the RyR2- Ca2+- release channel.19 The present 
experiments nevertheless first confirmed that 8- CPT acutely produced 
arrhythmic substrate. Admittedly, steady extrinsic pacing, whether be-
fore or following pharmacological intervention, did not induce arrhyth-
mia, but nevertheless provided the AP parameters of APD and latency. 
Nevertheless, both extrinsic pacing at progressively increased frequen-
cies and programmed applications of extrasystolic (S2) stimuli induced 
VT in 8- CPT- treated but not untreated hearts during monophasic AP 
recordings. These also provided indications as to whether alterations in 
refractoriness properties took place. The protocols therefore together 
permitted the presence of absence of arrhythmia to be correlated with 
the corresponding presence or absence of alterations in particular AP 
parameters.
Secondly, the arrhythmic effects of 8- CPT challenge were accom-
panied by a slowed CV as reflected in changes in AP latencies. However, 
it did not affect the AP recovery properties of APD and VERP.
Thirdly, pharmacological manipulations using the RyR2 antago-
nist dantrolene corroborated these findings. Multiple studies have 
demonstrated that dantrolene reduces RyR2- mediated Ca2+ leak, 
decreasing the incidence and duration of Ca2+ sparks in cultures 
of cardiomyocytes modelling both CPVT26 and cardiac failure.27,28 
Dantrolene may enhance the interactions between the N- terminal 
and the central domain of the RyR2 molecule. These interactions 
stabilise the closed state of the channel.26 Furthermore dantrolene 
shows an increased binding following modification of the RyR2 
conformation by both EGTA, and during cardiac failure. Thus, dan-
trolene inhibited RyR2 Ca2+ release particularly under conditions of 
increased channel open probability.26,27,35 The present experiments 
demonstrated that applied by itself, dantrolene altered neither ar-
rhythmic tendency nor AP conduction and recovery parameters. 
However, it reversed the actions of 8- CPT. Thus when both drugs 
were added in combination, there was no arrhythmia, and AP param-
eters were restored to normal.
Together these findings suggest that reversible arrhythmic effects 
related to slowed AP propagation but unchanged AP recovery can fol-
low acute modifications of Ca2+ homeostasis accompanying interven-
tions increasing RyR2- mediated sarcoplasmic reticulum Ca2+ release. 
They complement previous observations of a longer term reduction in 
Control 8- CPT Dantrolene
Dantrolene 
with 8- CPT
No. of hearts showing incremental 
pacing induced VT
0a (n=9) 5ab (n=7) 0 (n=10) 0b (n=10)
No. of hearts showing S2- induced 
VT
0a (n=20) 4ab (n=8) 1 (n=13) 0b (n=13)
aIndicates where there is a significant increase in occurrence of VT in the presence of 8- CPT in com-
parison to control solution alone (P<.05).
bIndicates where there is a significant reduction in the occurrence of VT in the presence of dantrolene 
compared to 8- CPT alone (P<.05).
TABLE  1  Incidence of ventricular 
tachycardia (VT) observed with S1S2 PES 
and incremental pacing protocols
Activation parameter 8- CPT Dantrolene
Dantrolene 
+ 8- CPT
Latency 1.14±0.04 (n=7)a 1.04±0.03 (n=10) 1.09±0.05 
(n=8)
Recovery parameter
APD90 1.09±0.10 (n=5) 1.11±0.07 (n=8) 1.23±0.12 
(n=6)
BCL at onset of 2:1 
block
0.92±0.05 (n=4) 0.96±0.02 (n=5) 0.93±0.08 
(n=5)
VERP 1.10±0.11 (n=7) 0.99±0.13 (n=7) 0.95±0.13 
(n=6)
APD, action potential duration. BCL, basic cycle length; VERP, ventricular effective refractory period.
aIndicates where there is a significant increase in the ratio of AP conduction latency following treat-
ment with 8- CPT compared prior to treatment in the control condition, as shown by an increase in ratio 
of latency post- treatment vs pre- treatment (P<.01; n=7).
TABLE  2 Action potential (AP) 
parameters following pharmacological 
treatment normalised to control values in 
the same heart
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Nav1.5 expression following chronic alterations in Ca2+ homeostasis 
associated with the RyR2-P2328S mutation.10
4  | METHODS
All animals used for experiments were of the WT sv129 background. 
A total of 20 male and female, between the ages of 5 and 7 months, 
were used for the experiments. Mice were kept in animal house facili-
ties at 21°C and exposed to 12 hour dark : light cycle each day, with 
free access to sterile rodent chow, drinking water, and bedding at all 
times. All animals were killed by cervical dislocation by Home Office- 
licensed personnel. Procedures used conformed to Schedule 1 of the 
UK Animals (Scientific Procedures) Act (1986), and to Institutional 
Ethics Committee Guidelines. Procuration of animals, their husbandry 
and all experiments also conformed to the ‘European Convention 
for the Protection of Vertebrate Animals used for Experimental and 
other Scientific Purposes’ (Council of Europe No 123, Strasbourg 
1985). The hearts were isolated from the animal by bilateral ster-
notomy and placed upon ice- cold Krebs- Henseleit (KH) solution 
(pH 7.4; NaCl [119 mmol/L], NaHCO3 [25 mmol/L], KCl [4 mmol/L], 
MgCl2 [1 mmol/L], KH2PO4 [1.2 mmol/L], CaCl2 [1.8 mmol/L], glucose 
[10 mmol/L] and sodium pyruvate [1.8 mmol/L]); the solution was 
bubbled through with 95% O2 and 5% CO2 (British Oxygen Company, 
Manchester, UK).
The heart was dissected free of connective tissue to expose 
3- 4 mm of aorta. The aorta was cannulated with a tailor- made 
21- gauge cannula pre- filled with cold KH solution, and a micro- 
aneurysm clip (Harvard Apparatus, Cambridge, UK) was used to 
fix the cannula into place. Thereafter, the heart was quickly placed 
within the perfusion system. KH solution used to perfuse the heart 
was first passed through a 200 μm followed by a 5 μm filter, and 
warmed to 37°C by a water jacket and circulator. A peristaltic pump 
(Watson- Marlow Bredel pumps model 505S, Falmouth, Cornwall, 
UK) was used to deliver the perfusion fluid at a constant rate of 
2.3 mL/min. After commencement of continuous perfusion, hearts 
were investigated for spontaneous contractions and confirmatory 
signs of viability.
Perfused hearts were extrinsically paced using a bipolar Ag/AgCl 
stimulating electrode placed on the right ventricular epicardium. The 
stimulus voltage on the constant voltage stimulator (stimulator model 
DS2A- MkII; Digitimer, Welwyn Garden City, Herts, UK) was set to de-
liver stimuli at double the threshold voltage. The isolated Langendorff- 
perfused WT murine hearts were paced at 8 Hz for at least 15 minutes 
before beginning MAP recordings from the left ventricular epicardium, 
midway between ventricular apex and base, using a MAP electrode 
(Linton Instruments, Linton, Cambs, UK). The relative dimensions of 
the MAP electrodes and of the murine ventricles permitted only a sin-
gle channel of MAP recording at any given time The recorded data 
was amplified with a NL100AK head stage pre- amplifier, followed 
by a NL104A amplifier (Digitimer). The signal was then band pass 
filtered (filter range 0.5 Hz- 1 kHz; Neurolog model NL125/6 filter; 
Digitimer) and digitised (1401plus MKII; Cambridge Electronic Design, 
Cambridge, UK). All MAP traces were recorded electronically, and the 
waveforms analyzed using Spike2 software (Cambridge Electronic 
Design).
Experiments were carried out under the following conditions, de-
fined by the perfusate used for the heart.
1. The control procedure used KH solution alone without any added 
pharmacological agents.
2. 8-CPT (8-pCPT-2′-O-Me-cAMP: 8-(4-chlorophenylthio)-2′-O-
methyladenosine-3′,5′-cyclic monophosphate; BIOLOG Life 
Science Institute, Bremen, Germany) was made into a stock of 
1 mmol/L with dimethyl sulfoxide (DMSO; stored at −20°C). When 
needed for use, the stock was then diluted in KH solution to make 
up a final concentration of 1 μmol/L 8-CPT, in accord with that pre-
viously used in the earlier study.24
3. Dantrolene sodium (Sigma-Aldrich, Poole, Dorset, UK) was dis-
solved in DMSO to make a 5 mmol/L stock (stored at 4°C). The final 
concentration of 5 μmol/L of dantrolene used in experiments were 
obtained by dilution of the stock with KH solution. Following con-
trol recordings, the pharmacological manoeuvres involved applica-
tions of either 8-CPT alone (1 μmol/L) followed by treatment with 
both 8-CPT and dantrolene (1 μmol/L and 5 μmol/L respectively), 
or dantrolene alone (5 μmol/L) followed by treatment with both 
drugs. During these procedures, hearts were paced at 8 Hz for at 
least 3 minutes after the estimated time of drug arrival at the heart 
before recordings were made.
All data are expressed as mean±SEM; where time is the variable, data 
is presented in milliseconds (ms). The number of hearts from which data 
is derived from for each condition is designated n. For categorical data, 
Fisher’s exact test was used to test for statistical significance between 
two data sets, each with two possible outcomes, the presence or ab-
sence of VT. Changes in the continuous parameters of AP latency, AP du-
ration at 90% recovery (APD90), basic cycle length (BCL) at the onset of 
2:1 block, and VERPs were tested using Student’s paired t- test. Statistical 
significance obtained from the t- test was defined as P<.05.
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